Why did Zoetis raise its full-year 2025 guidance?

Management attributed the raise to strong first-half performance and continued discipline in execution and cost management. Revenue guidance moved up by $25 million at the low and high ends, organic operational growth guidance rose to 6.5% to 8.0%, and adjusted EPS guidance rose by $0.10 to $6.30 to $6.40.

How much of the growth came from underlying business versus currency and divestitures?

Reported revenue grew 4%, but organic operational growth was 8% because foreign exchange reduced revenue by about 1% and the MFA divestiture reduced it by about 3%. Companion animal growth was almost entirely organic at 8%, while livestock declined 8% reported but rose 6% organically.

Why is there a large gap between GAAP and adjusted earnings?

Adjusted results exclude purchase accounting adjustments, acquisition and divestiture costs, and certain significant items. In Q2 these totaled about $65 million pre-tax, including asset impairments, restructuring related to shifting certain products to external manufacturing, and costs of a multi-year ERP-based business transformation program. Management expects about $75 million of such items for full-year 2025.

What are the main risks to the outlook?

The filing points to foreign exchange movements, announced and enacted tariffs, and competitive pressure, such as on Draxxin in livestock. Weakness in the Librela and Solensia osteoarthritis pain antibodies and the timing of ceftiofur supply also affected the quarter. Guidance reflects late-July FX rates and may change with these factors.

ZTS 8-K: Earnings & Results

01—Abstract

Summary

Summary of the 8-K filed August 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Zoetis reported second-quarter 2025 results on August 5, 2025, with revenue of $2.46 billion^a, up 4% reported and 8% on an organic operational basis, and GAAP net income of $718 million ($1.61 diluted EPS), up 15% and 18% respectively.

Adjusted net income was $783 million^b, or $1.76 per diluted share, up 10% and 13%. Growth was led by the U.S. and International companion animal franchises, particularly Simparica Trio and dermatology products such as Apoquel and Cytopoint. Livestock was the weak spot, down 8% reported, reflecting the divestiture of the medicated feed additive portfolio and competitive pressure on Draxxin, while the Librela and Solensia osteoarthritis pain mAbs also declined in the U.S. Management raised full-year 2025 guidance across the board.

Revenue is now expected at $9.450 to $9.600 billion^c, up from $9.425 to $9.575 billion, with organic operational growth of 6.5% to 8.0%. Adjusted diluted EPS guidance rose to $6.30 to $6.40 from $6.20 to $6.30, and adjusted net income guidance rose to $2.825 to $2.875 billion. Reported diluted EPS guidance is $5.90 to $6.00, reflecting roughly $0.40 of significant items and purchase accounting.

Guidance assumes late-July foreign exchange rates and reflects enacted and announced tariffs. For investors, the quarter shows broad-based organic growth and disciplined cost management, with adjusted cost of sales falling to 26.3%^d of revenue from 28.3%.

Reported results carry a notable gap to adjusted figures, driven by purchase accounting, restructuring, and a business process transformation program, so investors should weigh both GAAP and non-GAAP measures. The filing is furnished under Item 2.02 rather than filed, so its contents are not incorporated into Securities Act registration statements.

02—Key points

Key Highlights

Q2 2025 revenue of $2.46 billion grew 4% reported and 8% organic operational, with U.S. revenue up 4% and International up 3% (9% organic operational).
GAAP diluted EPS of $1.61 rose 18%; adjusted diluted EPS of $1.76 rose 13%, and adjusted net income reached $783 million.
Companion animal revenue rose 8% to $1.79 billion, led by Simparica Trio and dermatology products Apoquel and Cytopoint, while livestock fell 8% to $638 million largely due to the MFA divestiture.
Full-year 2025 revenue guidance was raised to $9.450 to $9.600 billion, and adjusted diluted EPS guidance to $6.30 to $6.40 from $6.20 to $6.30.
Adjusted cost of sales improved to 26.3% of revenue from 28.3% a year earlier, supporting margin expansion.
Significant items in Q2 totaled $47 million pre-tax, including a $27 million asset impairment and an $11 million business process transformation charge (ERP implementation), and full-year significant items guidance rose to about $75 million.
Reported EPS guidance of $5.90 to $6.00 remains well below adjusted guidance, reflecting roughly $0.40 per share of purchase accounting and significant items.

03—Questions

Frequently Asked Questions

Why did Zoetis raise its full-year 2025 guidance?
Management attributed the raise to strong first-half performance and continued discipline in execution and cost management. Revenue guidance moved up by $25 million at the low and high ends, organic operational growth guidance rose to 6.5% to 8.0%, and adjusted EPS guidance rose by $0.10 to $6.30 to $6.40.
How much of the growth came from underlying business versus currency and divestitures?
Reported revenue grew 4%, but organic operational growth was 8% because foreign exchange reduced revenue by about 1% and the MFA divestiture reduced it by about 3%. Companion animal growth was almost entirely organic at 8%, while livestock declined 8% reported but rose 6% organically.
Why is there a large gap between GAAP and adjusted earnings?
Adjusted results exclude purchase accounting adjustments, acquisition and divestiture costs, and certain significant items. In Q2 these totaled about $65 million pre-tax, including asset impairments, restructuring related to shifting certain products to external manufacturing, and costs of a multi-year ERP-based business transformation program. Management expects about $75 million of such items for full-year 2025.
What are the main risks to the outlook?
The filing points to foreign exchange movements, announced and enacted tariffs, and competitive pressure, such as on Draxxin in livestock. Weakness in the Librela and Solensia osteoarthritis pain antibodies and the timing of ceftiofur supply also affected the quarter. Guidance reflects late-July FX rates and may change with these factors.

04—Continue

← View all 8-K filings